Reduction in size of prolactin-secreting tumours in men treated with pergolide.
The effect of pergolide mesylate was studied in two previously untreated men with large prolactinomas and exceptionally high prolactin concentrations. The study was designed to determine whether pergolide would be effective in alleviating symptoms, correcting hormonal abnormalities and shrinking the tumour. Starting with 50 micrograms daily the dose of pergolide was slowly increased over 10 weeks to 1 mg once daily, when repeat assessment was performed. Both patients reported complete relief of symptoms, with no side effects. Serum prolactin concentration was suppressed to normal in both subjects, and evidence to suggest tumour shrinkage was observed. Pergolide appears to be effective treatment for men with large prolactinomas.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010479:Pergolide; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D000970:Antineoplastic Agents; D004873:Ergolines; D010479:Pergolide; D011388:Prolactin